News by subject: TRI

A new study in mice shows that replacement of a dysfunctional gene could prolong survival in some people with arrhythmogenic right ventricular cardiomyopathy (ARVC), a rare inherited disorder in which the muscular walls of the heart progressively...

Florida Cancer Specialists & Research Institute, LLC (FCS) continues to advance the treatment of gastrointestinal and genitourinary cancers, as evidenced by participation at two global gatherings held this month and sponsored by the American Society...

Sound Pharmaceuticals (SPI) will present the Phase 2b STOP Ototoxicity data that was selected for podium presentation at the Association for Research in Otolaryngology (ARO) Midwinter Meeting in Anaheim, CA (February 3-7). This initial safety and...

NetraMark Holdings Inc. (the "Company" or "NetraMark") a generative AI software leader in clinical trial analytics, announces that it has signed a third contract with a large publicly listed biopharmaceutical company, pursuant to the Master...

Amyotrophic lateral sclerosis (ALS), a neurodegenerative disorder, is a significant global health issue, affecting the voluntary motor nervous system in affected individuals. It is further compounded by a lack of effective treatment options. This...

The Lupus Research Alliance (LRA) is pleased to grant the 2023 Dr. William E. Paul Distinguished Innovator Award (DIA) to Akiko Iwasaki, Ph.D., Sterling Professor of Immunobiology at the Yale School of Medicine. Dr. Iwasaki will investigate a...

IceCure Medical Ltd. ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced the U.S. Food and Drug...

Meru Health, a technology-enabled digital mental health provider with a novel mind-body approach to mental healthcare, published a retrospective cohort study in collaboration with University of Oregon, Harvard University, University of North Carolina...

Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") , a clinical-stage biotechnology company leveraging its proprietary Diffuspheretm technology to optimize drug delivery for applications with significant unmet need, today announced positive...

Chemomab Therapeutics Ltd. ...

Iterum Therapeutics plc (Iterum), a clinical-stage pharmaceutical company focused on developing next-generation oral antibiotics to treat infections caused by...

Today, Astellas Pharma Canada, Inc. announced that Health Canada has approved a supplemental New Drug Application for XTANDI® (enzalutamide) in a new prostate cancer treatment setting. With this approval, XTANDI becomes the first and only androgen...

Kodiak Sciences Inc. , a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that first time results of the KSI-501ABC Phase 1 Study...

NeoImmuneTech, Inc....

Matisse Pharmaceuticals B.V., a clinical stage company developing a medicinal product for the treatment of sepsis, today announced topline results from the HistoSeps trial evaluating the safety, tolerability and pharmacokinetics of intravenously (IV)...

EicOsis Human Health, a pharmaceutical company engaged in the development of a novel category of non-narcotic oral analgesics centered around the inhibition of the soluble epoxide hydrolase (sEH) enzyme, today announced the next step in its ongoing...

The interim analysis results from the phase III INSPIRE study of iruplinalkib developed by Qilu Pharmaceutical, which focuses on the first-line treatment of locally advanced or metastatic anaplastic lymphoma kinase (ALK)-positive non-small cell lung...

DP Technology, an "AI for Science" new paradigm-driven company, today announced the...

Eilean Therapeutics LLC, a biopharmaceutical company dedicated to discovering and developing best-in-class and first-in-class small molecule inhibitors to target escape mutations in hematologic and solid malignancies, today announced the clearance...

Halozyme Therapeutics, Inc. ("Halozyme") today announced that Takeda received European Commission (EC) approval for HYQVIA® [Immune Globulin Infusion 10% (Human)] co-formulated with Halozyme's ENHANZE® drug delivery technology as maintenance therapy...

Theragent Inc., a comprehensive CDMO focused on advancing next-generation cell-based therapies, has announced that its sponsor client, CellVax Therapeutics Inc., received clearance of its Investigational New Drug application (IND) by the U.S. Food...

Meeting Protocol Worldwide, a leading provider of life sciences services for clinical trial patients and industry meetings, is excited to announce today's launch of a complete rebranding....

Subcutaneous injection of the immunotherapy nivolumab (brand name Opdivo) is noninferior to intravenous delivery and dramatically reduces treatment time in patients with renal cell carcinoma, as reported by Dr. Saby George of Roswell Park...

Eilean Therapeutics LLC, a biopharmaceutical company dedicated to discovering and developing best-in-class and first-in-class small molecule inhibitors to target escape mutations in hematologic and solid malignancies, today announced the completion...

Insightec, a pioneer and global leader in focused ultrasound, has welcomed a positive recommendation report[1] from the Dutch Healthcare Institute (Zorginstituut Nederland, ZIN) to have MR-guided focused ultrasound (MRgFUS) reimbursed for people...

Rise Therapeutics, a clinical-stage biotechnology company developing novel oral immunotherapeutic medicines, today announced that it has enrolled its first patient in its R-2487 Phase 1 rheumatoid arthritis clinical trial....

SiRNA technology offers distinct advantages over conventional approaches, with the potential to target virtually any gene. This technology has emerged as a great strategy for treating a range of diseases, including cancer, viral infections, and...

Artivion, Inc. , a leading cardiac and vascular surgery company focused on aortic...

Oricell Therapeutics (Oricell), a clinical-stage biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for OriCAR-017 for patients with...

IceCure Medical Ltd. ("IceCure" or the...

Ractigen Therapeutics, a clinical-stage pharmaceutical company leading the charge in small activating RNA (saRNA) therapeutics, announces a formal collaboration with University Medical Center Utrecht, affiliated with Utrecht University. This...

Peijia Medical Limited (Peijia, (9996.HK)), a leading Chinese domestic player in the high-growth transcatheter valve therapeutic and neurointerventional procedural medical device markets, today announced the completion of patient enrollment and...

Bio-Techne Corporation today announced that Advanced Cell Diagnostics (ACD), a Bio-Techne spatial biology brand, has set a new standard with the development of a next-generation, protease-free RNAscope spatial multiomics...

In the Phase 2b trial, 100% (5 of 5) of ibezapolstat-treated patients who agreed to observation for up to three months following Clinical Cure of CDI experienced no recurrence of infectionFurther analyses will be forthcoming as data become available...

Ascidian Therapeutics, a biotechnology company aspiring to treat human diseases by rewriting RNA, today announced that the U.S. Food and Drug Administration...

Asieris Pharmaceuticals (Stock Code: 688176.SH), a global biopharmaceutical company specializing in discovering, developing, and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced the...

Asieris Pharmaceuticals (Stock Code: 688176.SH), a global biopharmaceutical company specializing in discovering, developing, and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced the...

Celltrion USA today announced the submission of Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for CT-P47, a biosimilar candidate of the reference product ACTEMRA® (tocilizumab)[1]....

Aadi Bioscience, Inc. , a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathway alterations, today announced poster presentations at the 2024 American Society of Clinical Oncology...

Astellas Pharma Inc. (TSE:4503, President and CEO: Naoki Okamura, "Astellas")...

CellMax Life, a molecular diagnostics company with proprietary technology for pre-cancer and cancer detection blood tests, presented the latest results from its independent external validation study on January 20, 2024 at the ASCO Gastrointestinal...

ChromaCode, Inc., a pioneering genomics multiplexing platform company developing accessible and affordable laboratory-based solutions, today announced the publication of a study entitled "NSCLC Digital PCR Panel Returns Low Input Sample Results Where...

Despite demonstrating significant clinical efficacy against various diseases, the widespread use of Traditional Chinese Medicine (TCM) is still limited. This is mainly due to the complexity in their formulation and lack of sufficient pharmacological...

Flare Therapeutics Inc., a biotechnology company targeting transcription factors (TF) to discover precision medicines for cancer and other diseases, today announced a poster presentation outlining the Phase 1 clinical trial design of FX-909, a highly...

Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced that one of its leading nanoformulation drug products had received promising...

Vanda Pharmaceuticals Inc. (Vanda) today announced the publication of an article titled "The Efficacy of Tradipitant in Patients with Diabetic and Idiopathic Gastroparesis in Phase III Randomized Placebo-Controlled Clinical Trial" in the Clinical...

Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in patients with mCRPC Phase 2 dose expansion currently underway at the RP2CDs of masofaniten 600 mg BID in combination with...

Nanotechnology-based drug delivery systems (DDS) offer several advantages, such as enhanced bioavailability and controlled drug release with reduced dosage. Recently, Sahmyook University researchers have developed a light-responsive DDS to treat skin...

MitoSense Inc., a leading innovator in biotechnology with a focus on neurodegenerative diseases, in collaboration with Uppsala University, Elliott Mitochondrial Center, and the Sallie Astor Burdine Breast Foundation in Baton Rouge, Louisiana, USA,...

Lindus Health, an anti-CRO running radically faster, more reliable clinical trials for life science pioneers, is announcing the appointment of Professor Robert S. Langer, renowned scientist, Institute Professor at Massachusetts Institute of...